Cancer Treatment News
🇪🇺 EMAEMA breaking news and regulatory updates for BD, investors, and analysts
Showing 1–7 of 7 articles
ASCO 2026: Olverembatinib Data & Gastric Cancer Trial Updates
EMA Recommends Adstiladrin Gene Therapy for Bladder Cancer Treatment in March 2026
TRI-611 Receives FDA Fast Track Designation for ALK-Positive Non-Small Cell Lung Cancer as Competition Intensifies
TME Pharma NOX-A12 Triple Therapy Shows Promise in Brain Cancer GLORIA Trial Published in Nature Communications
EMA Conditional Approval CAR-T Therapy for Relapsed B-Cell Lymphoma
EMA Issues Positive Opinion for Zepzelca (Lurbinectedin) in Cancer Treatment
EMA Issues Positive Opinion for Adstiladrin Gene Therapy in Bladder Cancer Treatment